You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

  

Mass. movers

Bank upgrade reportedly lifts Biogen Idec

Biogen Idec recently won a 15-year patent protection for its MS pill Tecfidera.

Essdras M Suarez/Globe Staff/File

Biogen Idec recently won a 15-year patent protection for its MS pill Tecfidera.

Continue reading below

A reported jump in Biogen Idec Inc.’s price target and a ratings upgrade from Bank of America/Merrill Lynch boosted the biotech company’s shares. Wall Street analysts said the company’s gains were due to the report, according to MarketWatch. Bank of America says it will not make the research document public. But several analysts said the paper reportedly boosted Biogen Idec’s price target to $246 from $187 a share, and upped the rating on the stock to buy from neutral.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week